Group 1 - The core revenue for the company reached approximately RMB 2.618 billion, representing a year-on-year increase of about 37.7% [1] - Gross profit was approximately RMB 1.802 billion, with a year-on-year increase of about 45.1% [1] - The company reported a profit attributable to owners of approximately RMB 180 million, marking a turnaround from loss to profit, with basic earnings per share of 1.97 cents [1] Group 2 - Revenue from the medical beauty business was approximately RMB 1.485 billion, showing a year-on-year increase of about 99.6% [1] - The core product, LetibotulinumtoxinA, expanded its coverage to over 8,000 medical beauty institutions, contributing significantly to revenue growth [1] - The company plans to pay a final dividend of 0.96 cents per share [1] Group 3 - Revenue from innovative drugs and other pharmaceuticals was approximately RMB 176 million, a year-on-year increase of about 206.3% [2] - The company aims for a strategic transformation in 2026, focusing on high-quality development and value release [2] - The core strategy includes deepening compliance, accelerating global layout, and enhancing capital efficiency to drive cross-sectional growth [2]